Concepedia

Selective tissue factor/factor VIIa Inhibitor, ER-410660, and its prodrug, E5539, have anti-venous and anti-arterial thrombotic effects with a low risk of bleeding

Tadashi Nagakura, Kimiyo Tabata, Kazunobu Kira, Shinsuke Hirota, Richard J. Clark, Fumiyoshi Matsuura, Hironobu Hiyoshi

Thrombosis Research · 2013 · 13 citations · 13 references

DOI

Concepts

References

13

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

Stuart J. Connolly, Michael D. Ezekowitz, Salim Yusuf et al. · New England Journal of Medicine · 2009 · 11.1K citations · Full text

Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism

Sam Schulman, Clive Kearon, Ajay K. Kakkar et al. · New England Journal of Medicine · 2009 · 2.5K citations · Full text

In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate

Thrombosis and Haemostasis · 2007 · 246 citations

Adhesive receptor Mac-1 coordinates the activation of factor X on stimulated cells of monocytic and myeloid differentiation: an alternative initiation of the coagulation protease cascade.

Dario C. Altieri, James H. Morrissey, T S Edgington · Proceedings of the National Academy of Sciences · 1988 · 212 citations · Full text

, , +20

Dose-Response Study of Recombinant Factor VIIa/Tissue Factor Inhibitor Recombinant Nematode Anticoagulant Protein c2 in Prevention of Postoperative Venous Thromboembolism in Patients Undergoing Total Knee Replacement

Agnes Lee, Giancarlo Agnelli, Harry Büller et al. · Circulation · 2001 · 166 citations